Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854029 · ClinicalTrials.gov registry record · Phase 4
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
A Phase 4 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 450
- Enrollment target
NCT06854029 is a Phase 4 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 450 participants.
The verdict
NCT06854029, a Phase 4 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 450 participants
- Enrollment target
Study Summary
The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.
Interventions
- DRUG Cabotegravir Injection
- DRUG Cabotegravir Pill
- DRUG Buprenorphine injection
- DRUG Buprenorphine Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06854029
The ClinicalTrials.gov registry entry for NCT06854029 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cabotegravir Injection is the first listed.
NCT06854029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06854029 about?
NCT06854029 is a clinical study titled "NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings". The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phas...
What is the current status of trial NCT06854029?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 450 participants. The study started on 2026-07-01. Estimated completion is 2030-06-01.
What interventions are being tested in trial NCT06854029?
The interventions under investigation include: Cabotegravir Injection (DRUG), Cabotegravir Pill (DRUG), Buprenorphine injection (DRUG), Buprenorphine Pill (DRUG).
Who is sponsoring clinical trial NCT06854029?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.